Results of a national consensus workshop: Therapeutic algorithm in patients with follicular lymphoma - Role of radioimmunotherapy

Annals of Hematology

Volumn 86, Issue 2, 2007, Pages 81-87

  Dreyling, Martin ^a   Trumper L ^b   von Schilling, C ^c   Rummel, M ^d   Holtkamp, U ^e   Waldmann, A ^e   Wehmeyer, J ^f   Freund, M ^g  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e German Leukemia and Lymphoma Help (DLH)   (Germany)

^f University of Rostock ^*

^g UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Follicular lymphoms; Radioimmunotherapy; Therapeutic algorithm

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; MELPHALAN; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ADVANCED CANCER; ALGORITHM; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; CONSENSUS; DRUG DOSE ESCALATION; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; HUMAN; MONOTHERAPY; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SIDE EFFECT; WORKSHOP;

ALGORITHMS; GERMANY; HUMANS; LYMPHOMA, FOLLICULAR; MEDICAL ONCOLOGY; NEOPLASM STAGING; RADIOIMMUNOTHERAPY; RECURRENCE; TIME FACTORS;

EID: 33845704776     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0207-0     Document Type: Article

References (41)

1. Winter J (2004) Low-grade lymphoma. Hematology: American Society of Hematology, Educational Program Book, pp 208-212
2. Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475
3. Young RC et al (1988) The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Semin Hematol 25(2):11-16
4. Horning SJ (2000) Follicular lymphoma: Have we made any progress? Ann Oncol 11(Suppl 1):23-27
5. Brice P et al (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15:1110-1117
6. Ardeshna KM et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomized controlled trial. Lancet 362:516-522
7. Tsimberidou AM et al (2002) Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 100(13):4351-4357
8. Rohatiner AZS et al (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215-2223
9. Schouten HC et al (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 21(21):3918-3927
10. Lenz G et al (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667-2674
11. Mc Laughlin P et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833
12. Ghielmini M et al (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with standard weekly x 4 schedule. Blood 103(12):4416-4423
13. Hiddemann W et al (2005) Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first-line therapy of follicular lymphoma. Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 106:3725-3732
14. Herold M et al (2004) Results of a prospective open-label phase III-trial: R-MCP vs. MCP alone in untreated advanced indolent lymphoma and MCL. Blood 104 (Suppl. 11):169a (abstract # 584)
15. Marcus R et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4):1417-1423
16. Dreyling MH et al (2005) Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Proc Am Soc Clin Oncol 23:567s (abstract #6528)
17. Hiddemann W et al (2005) Rituximab maintenance following a Rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood 106(11):270a (abstract #920)
18. 90Y]-Zevalin®. Empfehlung der Strahlenschutzkommission. 198. Sitzung am 17.02.2005
19. Witzig TE et al (2003) Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21:1263-1270
20. Witzig TE et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20(10):2453-2463
21. Gordon LI et al (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5(2):98-101
22. Gordon LI et al (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase I/II-study. Blood 103:4429-4431
23. Emmanouilides C et al (2006) Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 47(4):629-636
24. Schilder RJ et al (2004) Follow-up results of a phase II-study of ibritumomab radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 19(4):478-481
25. Schilder RJ et al (2005) Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed or refractory NHL. Proc Am Soc Clin Oncol 23:575s (abstract #6562)
26. 131 I tositumomab in 1,177 patients with low-grade, follicular, and transformed non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 23:575s (abstract #6561)
27. 131 I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449
28. Sweetenham JW et al (2004) Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. Blood 104(11):720a (abstract #2632)
29. Horning SJ et al (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23(4):712-719
30. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 21:266a (abstract #1062)
31. 131 I tositumomab: Efficacy and safety in 141 patients with previously untreated low-grade non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 23:575s (abstract #6560)
32. Press OW et al (2003) A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102(5):1606-1612
33. Shipley DL et al (2004) Phase II trial of Rituximab and short duration chemotherapy followed by 90 Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 23:560 (abstract #6519)
34. Shipley DL et al (2005) Rituximab with short duration chemotherapy followed by 90 Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 23:579s (abstrac #6577)
35. Schilder R et al (2004) Subsequent therapy for non-Hodgkin's Lymphoma is feasible after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan (Zevalin®). Hem J 5(Suppl 2):S7 (abstract #019)
36. Ansell SM et al (2004) Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive Non-Hodgkin's lymphoma: A review of the literature. Clin Lymphoma 5(3):202-204
37. Gordon L et al (2001) High-dose therapy can be safely and successfully administered after Zevalin® treatment. Proc Am Soc Clin Oncol 20:232b (abstract #2681)
38. Nademanee A et al (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. J Clin Oncol 106:2896-2902
39. Winter J et al (2004) Zevalin® dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma. Blood 103(11):329a (abstract #1162)
40. Krishnan AY et al (2005) The outcome of ZBEAM, a regimen combining 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 23:576s (abstract #6566)
41. 90 Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: Results of two phase II trials of the European MCL Network and the PLSG. Proc Am Soc Clin Oncol 24:422s (abstract #7502)